Rowsley can raise value by divesting non-core assets
IF billionaire Peter Lim had wanted to realise the fullest
value for the Thomson Medical healthcare group, an initial public offering
(IPO) would have been the cleanest way to structure a deal.
By choosing instead to inject these healthcare assets into
Rowsley, the listed firm which he also controls, Mr Lim seems to be making an
effort to reverse the fortunes of the loss-making company with interests in a
mishmash of businesses including real estate, design consultancy and hotel
management.
On Monday, Rowsley inked a deal to acquire the Thomson
Medical's businesses from Mr Lim for S$1.6 billion, to be paid mostly in stock.
An IPO was certainly something Thomson had considered. In September last year,
Roy Quek, executive chairman of Thomson Medical and chief executive of TMC Life
Sciences, told The Business Times that the group was gunning for an initial
public offering. He told BT then: "If we were to do a listing now, we'd
probably have a market capitalisation of S$2 billion to S$3 billion. I think we
can do better. We're targeting S$5 billion for a start and trying to grow
that."
Asked to comment on the deal structure during Rowsley's
press conference held at Goodwood Park Hotel on Monday, Mr Quek told BT:
"This really is the prerogative of the owner. How he wants to structure
his ownership and his shareholding is not something that management should
comment on."
Mr Lim did not attend Rowsley's press conference at Goodwood
Park Hotel on Monday.
Certainly, the asset injection makes good sense for Mr Lim,
who will swap his 100 per cent stake in private firm Thomson Medical and 70.36
per cent stake in Malaysia-listed TMC Life Sciences for S$1.6 billion in
Rowsley shares and roughly S$40 million in cash.
Whether it is also a great deal for shareholders will depend
on how much growth the company can deliver.
For shareholders' bonus warrants to be in the money,
Rowsley's shares must trade above S$0.09 in the year following the asset
injection. For their piggyback warrants to be in the money, Rowsley's shares
must remain above S$0.12 four years after the bonus warrants are issued.
One concern is that Rowsley has a track record of issuing
new shares to fund acquisitions, and not always living up to expectations.
In 2007, Rowsley unveiled plans to acquire a China solar
energy firm by issuing S$2.7 billion worth of new shares. The firm had not sold
a single solar panel at the point and the deal was scrapped months later.
In 2013, Rowsley became a real estate player by acquiring
RSP Architects and a 9.23ha plot of land in Iskandar, Johor for S$545.5 million
in all-share deals. The land plot in Vantage Bay was majority-owned by Mr Lim.
The Vantage Bay project faced constant delays and was repositioned from a
residential, office and retail project into a healthcare hub in 2015, with
Thomson Medical roped in.
On Monday, Rowsley said that Thomson Iskandar Medical Hub,
comprising a 500-bed hospital and 400-suite medical tower would be completed in
2021.
Last year, Mr Quek declared plans to add 300 beds to the
187-bed Thomson Medical Centre at Thomson Road in Singapore. Rowsley's
announcements on Monday made no mention of this.
The group has yet to receive the relevant approvals from the
Health Ministry to execute. Mr Quek explained: "In Singapore, we're always
looking to expand. It's really a question of working with the authorities to
make sure that whatever we have planned is in line with what they have in their
own plans."
Clearly, Thomson Medical has faced challenges in realising
its expansive ambitions, and needs a good team to hit the ground running.
At the same time, Rowsley has said that healthcare will
become its main focus, and the proposed change in name from Rowsley to
"Thomson Medical Group" will reflect this.
It plans to undertake a strategic review of its real estate,
consultancy and hospitality assets once shareholders approve the acquisition in
the first quarter next year.
To raise shareholder value, Rowsley could consider disposing
of its non-healthcare assets to sharpen its focus on healthcare and shed its
image as a hotchpotch grouping of Mr Lim's varied interests.
Marissa Lee
19 December 2017
Comments